The significance of Epidermal Growth Factor Receptor uncommon mutations in Non-Small Cell Lung Cancer: a systematic review and critical appraisal

Despite the increase of therapeutic options available in clinical setting, non-small cell lung cancer (NSCLC) still remains the leading cause of cancer-related death in both sexes worldwide, representing over 85% of all lung cancers.[1] The clinical knowledge of the epidermal growth factor receptor (EGFR) molecular status, emerging over a decade ago, has led to a dramatic shift in the treatment paradigm of metastatic NSCLC. The prevalence of EGFR mutations ranges from 10% to 15% in Caucasian patients [2] and up to 50% in East-Asian patients, [3] mainly but not only with adenocarcinoma histology, female gender and quite peculiar of no smoker or former smoker patients.

Source: Cancer Treatment Reviews - February 20, 2020 Category: Cancer & Oncology Authors: Valerio Gristina, Umberto Malapelle, Antonio Galvano, Pasquale Pisapia, Francesco Pepe, Christian Rolfo, Silvia Tortorici, Viviana Bazan, Giancarlo Troncone, Antonio Russo Source Type: research